SAN FRANCISCO, May 15, 2017 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) announced today that its corporate
presentation will be webcast at the upcoming UBS Global Healthcare
Conference on Monday, May 22, 2017 at
1:30 p.m. Eastern time.
The presentation will be accessible via a Webcast through a link
posted on the Investors, Events Calendar section of the Nektar
website: http://www.nektar.com. This Webcast will be available for
replay for 14 days following the date of the presentation.
About Nektar
Nektar Therapeutics is a research-based development stage
biopharmaceutical company whose mission is to discover and develop
innovative medicines to address the unmet medical needs of
patients. Our R&D pipeline of new investigational medicines
includes treatments for cancer, auto-immune disease and chronic
pain. We leverage Nektar's proprietary and proven chemistry
platform in the discovery and design of our new therapeutic
candidates. Nektar is headquartered in San Francisco,
California, with additional
operations in Huntsville, Alabama and Hyderabad,
India. Further information about
the company and its drug development programs and capabilities may
be found online at http://www.nektar.com.
Contacts:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Jodi Sievers of Nektar Therapeutics
415-482-5593
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-ubs-global-healthcare-conference-2017-in-new-york-300457593.html
SOURCE Nektar Therapeutics